NIOX Group Plc | NIOX | AIM

NIOX Group (LSE:NIOX) has drifted back onto the radar of UK small-cap investors, and the reason is not hard to find: the market for point-of-care respiratory diagnostics is quietly becoming a growth story again. The AIM-listed company is the world's leading supplier of FeNO — fractional exhaled nitric oxide — testing, a quick, non-invasive breath test that helps clinicians diagnose and monitor asthma by measuring inflammation in the airways. After several years in which the shares went largely unremarked, a run of expanding testing volumes, better reimbursement and a strengthening Balance Sheet has brought the story firmly back into focus. That renewed attention comes with a caveat, however: a stock appearing on a market-gainers screen is only a point-in-time snapshot, and the more durable case rests on the fundamentals.

The business

NIOX operates a classic razor-and-blade model. It sells its NIOX VERO and newer NIOX PRO analysers to clinics, hospitals, pharmacies and research organisations, then earns high-margin, Recurring Revenue from the single-use test kits that each device consumes. Every additional analyser placed in the field therefore builds a larger installed base and a more predictable consumables stream. The group emerged from the former Circassia Business and has since sharpened its focus almost entirely onto FeNO, a market in which it holds a commanding global share. That concentration is both its greatest strength and, as discussed below, its principal risk.

Latest results

Full-year 2025 figures, published in March 2026, underlined the renewed momentum. Revenue rose 17% to £48.7m, while adjusted EBITDA climbed 21% to £16.7m, demonstrating the operational Leverage inherent in the model. The number of FeNO tests performed reached 7.2m, up 9%, and the clinical device base expanded by 7%. Research revenue — sales to pharmaceutical and academic customers — jumped 77%. Crucially, year-end cash almost doubled to £19.9m, giving the group ample flexibility. Having already paid a £5m Interim Dividend during the year, the board recommended a higher final payout, signalling confidence in the durability of cash generation.

Sector backdrop and catalysts

Management points to several structural tailwinds. These include record testing volumes, broadening insurance coverage for FeNO in the United States, improved reimbursement in Japan, and a growing body of clinical evidence supporting FeNO's use in COPD as well as asthma — a potentially significant expansion of the addressable population. Potential catalysts investors may watch include the commercial roll-out of the NIOX PRO analyser, progress on an early-stage home-use testing device, and further reimbursement decisions that could open new geographies or widen usage within existing ones.

Risks

The risks flow directly from the group's focus. NIOX is effectively a single-product company whose fortunes are tied to the pace of FeNO adoption and to reimbursement rulings in a handful of key markets. As an international exporter it carries currency exposure, and any slowdown in device placements would eventually feed through to consumables volumes. Competition, the tempo at which clinical guidelines embrace FeNO, and broader healthcare-budget pressures are all factors that could temper the growth trajectory.

What investors may watch

With a strengthened balance sheet, negligible Debt and a progressive dividend, NIOX (LSE:NIOX) arguably looks better placed than at almost any previous point in its listed life. The key question is whether the home-use ambition and the COPD opportunity can lift it from a profitable niche supplier into a broader respiratory-diagnostics platform. Liquidity in the shares is reasonable for an AIM name of its size, but the Investment case ultimately hinges on execution against those ambitions. Forthcoming interim results and any fresh reimbursement news will be the near-term signposts.